The agreement grants to MedImmune non-exclusive license rights to develop, manufacture and market antibodies based on Potelligent technology for an undisclosed number of targets. In return, BioWa receives from MedImmune certain fees and milestone payments during product development, as well as royalties on marketed products using antibody-dependent cellular cytotoxicity enhanced antibodies.
Dr Masamichi Koike, president and CEO of BioWa, said: “We are pleased to extend our relationship with MedImmune, a world-leading biologics business and the cornerstone to AstraZeneca’s plans to establish a major international presence in the R&D of biological therapeutics.”